1van Duin M, de Wit J, Odijk H, et al. Molecular characterization of the human excision repair gene ERCC - 1 : cDNA cloning and amino acid homology with the yeast DNA repair gene RADIO[J]. Cell,1986, 44(6) :913 - 923.
2Cheng L, Spitz MR, Hong WK, et al. Reduced expression levels of nucleotide excision repair genes in lung cancer: a case- control analysis[J]. Carcinogenesis, 2000, 21(8) : 1527 - 1530.
3Cheng L, Sturgis EM, Eicher SA, et al. Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck[J]. Cancer, 2002, 94(2) :393 - 397.
4Yu JJ, Mu C, Lee KB, Okamoto A, et al. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues[ J ]. Murat Res, 1997, 382( 1 - 2) : 13 - 20.
5Bicher A, Ault K, Kimmelman A. et al. Loss of heterozygosity in human ovarian cancer on chromosome 19q [J]. Gynecol Oncol,1997, 56(1) : 36 - 40.
6Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy[J]. J Clin Oncol,1998,
7Yen L, Woo A, Christopoulopoulos G, et al. Enhanced host cell reactivation capacity and expression of DNA repair genes in human breast cancer cells resistant to bi-functional alkylating agents[ J ].Mutar Res, 1995, 337(3): 179-189.
8Dunkern TR, Fritz G, Kaina B. Cisplatin-induced apoptosis in 43-3B and 27-1 cells defective in nucleotide excision repair[ J].Mutat Res, 2001, 486(4): 249-258.
9Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: Role of ERCC1-XPF[J]. Biochem Pharmacol, 2000, 60(9): 1305-1313.
10Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy[ J ]. Cancer Treat Rev,1998, 24(5): 331-344.
